

Dairy foods and cardiometabolic diseases: an update and a reassessment of the impact of SFA

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open Access

Givens, I. ORCID: <https://orcid.org/0000-0002-6754-6935>
(2023) Dairy foods and cardiometabolic diseases: an update
and a reassessment of the impact of SFA. *Proceedings of the
Nutrition Society*, 82 (3). pp. 329-345. ISSN 0029-6651 doi:
<https://doi.org/10.1017/S0029665123000083> Available at
<https://centaur.reading.ac.uk/111111/>

It is advisable to refer to the publisher's version if you intend to cite from the
work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1017/S0029665123000083>

Publisher: Cambridge University Press

All outputs in CentAUR are protected by Intellectual Property Rights law,
including copyright law. Copyright and IPR is retained by the creators or other
copyright holders. Terms and conditions for use of this material are defined in
the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online



© The Author(s), 2023. Published by Cambridge University Press on behalf of The Nutrition Society. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

The Nutrition Society Summer Conference 2022 was hosted collaboratively by Sheffield Hallam University, the University of Sheffield and Sheffield City Council on 12–15 July 2022

Conference on ‘Food and nutrition: Pathways to a sustainable future’ Symposium five: Understanding mechanisms for health

Dairy foods and cardiometabolic diseases: an update and a reassessment of the impact of SFA

D. Ian Givens

Institute for Food, Nutrition and Health, University of Reading, Reading RG6 6EU, UK

Type 2 diabetes (T2D) and CVD are major causes of mortality and chronic morbidity. Whilst mortality from CVD has decreased they remain the largest cause of death in Europe and the prevalence of T2D is increasing rapidly. A consistent component of public health advice is to reduce intake of SFA to reduce CVD in particular, which implies limiting dairy food consumption. The prospective studies and randomised controlled trials included in this review show that for dairy foods at least, SFA are not consistently associated with CVD or T2D risk. For CVD the association with dairy foods is generally neutral despite dairy foods being the major source of SFA in many diets. This creates considerable doubt, at least for dairy foods, concerning the validity of the traditional diet-heart hypothesis which positively relates SFA intake to increased serum LDL-cholesterol and subsequent increased CVD. There is now emerging evidence to explain this which is highly relevant to dairy foods. These include the potentially counterbalancing effect of SFA-stimulated HDL-cholesterol and specific food matrix factors. In addition, SFA are associated with the less atherogenic large buoyant LDL particles and possible counterbalancing hypotensive effects of dairy proteins. Overall, dairy foods have either a neutral or beneficial association with CVD and T2D. Beneficial associations are seen for blood pressure and the reduced T2D risk linked to yoghurt consumption, a subject that needs urgent attention given the sharp rise in T2D prevalence in many countries.

Key words: Saturated fat: Cholesterol: Milk: Dairy products: Diabetes: CVD

There is considerable concern about the continuing rise in the prevalence of type 2 diabetes (T2D), which in the UK increased from about 4000 age-standardised prevalence rates per 100 000 in 1990 to about 9000 age-standardised prevalence rates per 100 000 in 2020 in men⁽¹⁾. The trend in women is similar, albeit at a slower rate and with some evidence of plateauing at about 7000 age-standardised prevalence rates per 100

000 from 2015⁽¹⁾. Diabetes UK⁽²⁾ reports that treating diabetes costs the National Health Service approximately £14 billion per year and no doubt there will be additional indirect costs. Across the European Union there is considerable variability in the rate of standardised prevalence change over the past 30 years although for most European Union countries it has been less than that in the UK. Interestingly, in the UK and the European

Abbreviations: ACM, all-cause mortality; BP, blood pressure; BCAA, branched-chain amino acid; CEC, cholesterol efflux capacity; DNL, de novo lipogenesis; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; MI, myocardial infarction; RCT, randomised controlled trial; RR, relative risk; SBP, systolic blood pressure; T2D, type 2 diabetes; TC, total cholesterol; TFA, trans fatty acid.

Corresponding author: D. Ian Givens, email d.i.givens@reading.ac.uk

Union, increases in T2D prevalence have not been accompanied by an increase in associated mortality and indeed with a small reduction in some countries. However, certification of the cause of death in subjects with diabetes-induced CVD is complicated, with many not certified to have died from diabetes but from CVD⁽³⁾. Indeed subjects with T2D have two times the risk of CVD which is indeed often the actual cause of death⁽⁴⁾. Partly because of the close link between T2D and CVD, it is now common to include both under the umbrella term cardiometabolic diseases and this term is used in parts of the present paper.

Obesity, lack of physical activity and age are major risk factors for developing T2D with regular exercise being associated with up to a 50% reduction in the relative risk (RR)⁽⁵⁾. Diet is a further risk factor for T2D, in part because together with exercise, diet is related to obesity and also because dietary composition can influence insulin sensitivity which generally declines as part of the aetiology of T2D.

Whilst the mortality rate from CVD in the UK has fallen considerably over the past 50 years they remain the largest cause of death in UK males⁽⁶⁾. In addition, CVD remain the greatest cause of death in the European Union and has a major impact on healthcare costs⁽⁷⁾.

This short review concentrates on the associations between dairy foods and the risk of T2D and CVD. In addition, since dairy foods are often the greatest dietary source of SFA, the review will also look at recent evidence which casts doubt that dairy SFA are a risk factor for CVD.

Dairy consumption and risk of type 2 diabetes and CVD

Type 2 diabetes

Some early studies^(8–10) strongly suggested that consumption of dairy foods can moderate components of the metabolic syndrome which represents a set of risk factors including insulin resistance and abdominal obesity both of which can substantially increase the risk for T2D. A number of meta-analyses^(11–13) also concluded inverse associations between total dairy and low-fat dairy consumption and T2D. More recently, Imamura *et al.* reported on the association between biomarkers of dairy fat consumption and the incidence of T2D in a pooling study involving sixteen prospective studies⁽¹⁴⁾. In total this involved data from almost 64 000 adults of which about 15 000 became type 2 diabetics during the 20 years follow-up. Overall, the project showed that circulating fatty acid biomarkers of dairy fat intake (15:0, 17:0, *trans* 16:1n-7) were each associated with a lower risk of developing T2D independently of major risk factors for T2D such as age and obesity. Imamura *et al.* estimated that subjects with higher concentrations of the sum of the three biomarkers had a 29% (95% CI: 21, 37) lower risk of T2D than those with lower concentrations⁽¹⁴⁾. These findings supported the earlier work⁽¹⁵⁾ which also showed an inverse association between circulating *trans* 16:1n-7 and incident T2D. Unfortunately the fatty acid biomarker technique cannot differentiate between different dairy foods, nevertheless

this major study strongly pointed to beneficial effects of dairy foods on the risk of T2D. There were indications that the benefit was stronger in women than men.

Guo *et al.*⁽¹⁶⁾ reviewed the evidence from a range of meta-analyses of cohort studies plus some recently published cohort studies which examined the association of dairy foods and T2D. The overall conclusions indicated that dairy food consumption has a neutral or moderately beneficial effect on glucose homeostasis and T2D risk. It was also concluded that the meta-analysis of Soedamah-Muthu and de Goede⁽¹⁷⁾ showed good evidence of a non-linear inverse association between yoghurt consumption and T2D risk (RR 0.86, 95% CI: 0.83, 0.90) at an intake of 80 g/d compared with no yoghurt consumption. This conclusion was supported by another study⁽¹⁸⁾ which, based on the combination of three large US cohorts (34 224 men; 158 128 women), showed that increasing yoghurt intake by >0.5 servings/d was associated with a moderately reduced risk (RR 0.89, 95% CI: 0.82, 0.96) of T2D. Guo *et al.*⁽¹⁶⁾ noted that whilst some earlier studies with cheese showed a similar association to that of yoghurt, some more recent ones did not and indeed one⁽¹⁸⁾ reported an increased risk of T2D associated with consumption of >0.5 servings/d of cheese (RR 1.09, 95% CI: 1.02, 1.16). The systematic review and meta-analysis of seven prospective studies (nine populations) on fermented dairy products and cardiometabolic diseases⁽¹⁹⁾ reported that yoghurt consumption was associated with a 27% reduction in the risk of T2D (RR 0.73, 95% CI: 0.70, 0.76) although in three prospective studies cheese intake was associated with an increase in the risk of T2D (RR 1.24, 95% CI: 1.03, 1.49) although this association was NS in any of the three individual studies. A recent study⁽²⁰⁾ also showed a benefit of fermented dairy (≥ 2 cups/d) over unfermented dairy (≥ 4 cups/d) for a reduced risk of the metabolic syndrome in Asian Indians.

Overall, the evidence from prospective studies (Table 1) is suggestive that dairy foods are generally associated with a neutral risk of T2D apart from yoghurt which is indicative of a reduced risk. An understanding of the mechanism(s) involved in the consistent beneficial effects of yoghurt consumption on risk of T2D remains incomplete. Fernandez *et al.*⁽²¹⁾ suggest that calcium (Ca), protein, bioactive nutrients and live cultures present in yoghurts are likely to be contributors, but admit that their role within the food matrix is not known. Given the increasing prevalence of T2D and the consistent beneficial association with yoghurt consumption suggests that this topic needs to be investigated with urgency. Interestingly, a recent risk analysis⁽²²⁾ indicates that 200 000 US disability-adjusted life years (4.5%) due to T2D may be prevented by increased dairy consumption.

Milk proteins are rich sources of branched-chain amino acids (BCAA), leucine in particular. Whey protein in particular is used extensively to provide an anabolic stimulus, mediated mainly by leucine, to muscle protein synthesis in sports people⁽²³⁾ and the elderly⁽²⁴⁾. Recent data⁽²⁵⁾ indicate the world market for whey protein was worth approximately \$8.7 billion in 2019 which is expected to increase by a compound growth rate of 9.8% up to 2027. Europe is the largest market (34%) with Germany,

Table 1. Selection of dose–response meta-analyses examining the association of dairy food consumption and the risk of cardiometabolic diseases

Disease outcome/dairy foods	RR* (95 % confidence interval)	Reference
All-cause mortality		
Milk (per 244 g/d)	1.00 (0.93, 1.07)	37
Butter (per 14 g/d)	1.01 (1.00, 1.03)	46
Total dairy (>2 servings/d v. none)	0.83 (0.72, 0.9)	40
CHD		
Butter (per 14 g/d)	0.99 (0.96, 1.03)	46
CVD		
Milk (per 244 g/d)	1.01 (0.93, 1.10)	37
Cheese (per 10 g/d)	0.98 (0.95, 1.00)	37
Butter (per 14 g/d)	1.00 (0.98, 1.02)	46
Yoghurt (per 50 g/d)	1.03 (0.97, 1.09)	37
Total dairy (>2 servings/d v. none)	0.78 (0.67, 0.90)	40
Stroke		
Milk (per 200 g/d)	0.93 (0.88, 0.98)	141
Milk (per 200 g/d)	0.92 (0.88, 0.97)	17
Cheese (per 40 g/d)	0.97 (0.94, 1.01)	141
Butter (per 14 g/d)	1.01 (0.93, 0.99)	46
Total dairy (>2 servings/d v. none)	0.66 (0.53, 0.82)	40
Type 2 diabetes		
Butter (per 14 g/d)	0.96 (0.93, 0.99)	46
Yoghurt (per 80 g/d)	0.86 (0.83, 0.90)	142
Yoghurt (per 100 g/d)	0.94 (0.91, 0.97)	17
Yoghurt (>0.5 servings/d)	0.89 (0.82, 0.96)	18
Yoghurt (standardised dose–response not given) [†]	0.73 (0.70, 0.76)	19
Cheese (>0.5 servings/d)	1.09 (1.02, 1.16)	18
Cheese (standardised dose–response not given) [†]	1.24 (1.03, 1.49)	19

Adapted from⁽⁴¹⁾ and extended with additions based on this review.

* Relative risk. Note: equivalent values for Ref. 40 are hazard ratios.

[†] May be based on highest v. lowest in each study.

France, Spain and Italy followed by the UK consuming the largest proportion. Nutritional supplements have the greatest market share of whey proteins. It is therefore concerning that circulating BCAA concentrations have often been associated with an increased risk of T2D in cross-sectional and prospective studies^(26–29) and with an increased risk of CVD^(30,31). In the case-cohort study⁽³⁰⁾, BCAA were particularly associated with stroke risk in a high CVD risk population. The Tobias *et al.* study⁽³¹⁾ showed that the BCAA–CVD association was about 20% higher in women who developed T2D before CVD, but represented a risk similar to, but independent of, circulating LDL-cholesterol (LDL-C). It was suggested that BCAA may represent a biochemical phenotype of CVD risk which is common to T2D and may be related to early excess adiposity-related activity. A recent meta-analysis⁽³²⁾ using data mainly from mice studies confirmed that increasing dietary BCAA intake increases circulating BCAA concentration in a curvilinear fashion up to a diet BCAA concentration of about 0.5 kJ/g and a plateau blood concentration of about 40 µg/ml. This plateau effect is thought to be due to activation of branched-

chain α -keto acid dehydrogenase, a mitochondrial enzyme complex found in the liver and muscle, which reduces blood BCAA concentration. Increased BCAA intake increased plasma insulin concentrations and homeostatic model assessment of insulin resistance, and impaired glucose tolerance but was associated with reduced food and energy intake⁽³²⁾. Higher BCAA intake has been associated with a lower prevalence of overweight or obesity in human subjects⁽³³⁾.

Given the extensive use of whey protein in sport and other activities, the impact its BCAA may have on T2D and CVD risk in otherwise healthy young and old subjects warrants urgent attention.

CVD

A range of systematic reviews with meta-analyses on the outcomes of prospective cohort studies looking at the association between dairy foods and risk of CVD have been published over the past 20 years. Those published in the first 10 years of this century concluded that generally, high milk consumption did not increase the RR for CHD compared with low consumers⁽³⁴⁾. A further meta-analysis⁽³⁵⁾ combined data from prospective cohort and clinical studies and also showed no significant increase in the RR of CHD in high v. low milk consumers (RR 0.94, 95% CI: 0.75, 1.13). In recent years, the food dose–risk response meta-analysis methodology has been developed⁽³⁶⁾ which provides more insight into the associations between food intake and disease risk and provides information on the shape (e.g. non-linear) of the association. Such studies include a number^(17,36,37), which looked primarily at risk of CVD and other outcomes. In addition, two others^(38,39) have published extensive reviews on the subject of dairy food consumption and human health.

The PURE study⁽⁴⁰⁾ involved about 137 000 subjects aged 35–70 years living in twenty-one countries across five continents. After a 9.1 years of follow-up it examined the association between consumption of dairy products (total and milk, yoghurt and cheese) with non-CVD and CVD mortality and the risk of CVD. Higher consumption of total dairy foods (>2 servings/d v. none) was associated with lower risks of all-cause mortality (ACM) (hazard ratio (HR) 0.83, 95% CI: 0.72, 0.96; *P* trend = 0.0052), non-CVD mortality (HR 0.86, 95% CI: 0.72, 1.02, *P* trend = 0.046), CVD mortality (HR 0.77, 95% CI: 0.58, 1.01, *P* trend = 0.029), major CVD events (HR 0.78, 95% CI: 0.67, 0.90; *P* trend = 0.0001) and stroke (HR 0.66, 95% CI: 0.53, 0.82, *P* trend = 0.0003). Greater consumptions of milk and yoghurt, but not cheese, were associated with a lower risk of the combination of mortality or major CVD events. No significant association was seen with myocardial infarction (MI). In addition, butter intake was low and not significantly associated with disease outcomes. Whilst the outcomes are broadly in agreement with earlier studies and meta-analyses, this is believed to be the first study to involve such large and diverse sets of subjects with substantial variation in habitual intake of dairy and other foods between countries.



Givens⁽⁴¹⁾ summarised the outcomes of a number of dose–response meta-analyses on associations of various dairy food types with ACM, CVD and stroke. With some additions, these are summarised in Table 1 and overall are in good agreement with earlier findings that dairy food intake has a rather neutral association with the risk of CVD, although there are now indications of a negative association for consumption of milk and total dairy with the risk of stroke. Recent findings⁽⁴²⁾ agree with these findings reporting no significant associations between dairy intakes and risk of total CVD and CHD but also showing that an intake of at least 160 g/d fermented dairy foods (e.g. cheese and yoghurt) was associated with a reduced risk of cerebrovascular diseases compared with consumption of less than 57 g/d (HR 0.81, 95% CI: 0.66, 0.98). The recent findings of Olsson *et al.*⁽⁴³⁾ in about 80 000 Swedish participants agreed with the results of Sellem *et al.*⁽⁴²⁾ finding that milk consumption up to 800 g/d (compared with 100 g/d) was not clearly associated with risk of stroke (all types together), but found contrary results for milk and haemorrhagic stroke where an intake of 800 g/d (compared with 100 g/d) had an HR of 1.19 (95% CI: 1.03, 1.36). No associations were seen for fermented milk. Similarly, another study⁽⁴⁴⁾ also found no associations between total fermented dairy and ACM and CVD but found that high intake of fat-reduced milk was associated with a reduced risk of CVD (HR 0.84, 95% CI: 0.68, 1.03, *P* trend = 0.03) and ACM (HR 0.77, 95% CI: 0.61, 0.97, *P* trend = 0.004) compared with low intake. An umbrella review⁽⁴⁵⁾ of seventy-five meta-analyses reported on the association of food groups and risk of stroke. For ischaemic stroke, the association with high dairy *v.* low dairy intake was protective (RR 0.79, 95% CI: 0.78, 0.96) with similar results for haemorrhagic stroke (RR 0.75, 95% CI: 0.60, 0.94) although these results were related to only one meta-analysis. These findings highlight the importance of not assuming that all dairy products are the same and the importance of meta-analyses to examine the evidence from a range of different studies. There are few studies examining the association of butter consumption with CVD, but a dose–response meta-analysis⁽⁴⁶⁾ indicated no significant association between butter consumption and ACM, CVD, CHD or stroke. However this meta-analysis involved data from only a few studies (CVD *n* 4; CHD *n* 3; stroke *n* 3) and clearly further research on butter is required including a better understanding of the butter SFA-mediated increased HDL functionality⁽⁴⁷⁾ discussed later.

Overall, the findings from prospective cohort studies provide no consistent evidence of an increased risk of CVD/CHD with increased consumption of dairy foods, despite most of these foods often being the greatest dietary source of SFA intake. To many, this is counter-intuitive being contrary to the believed well-established link between SFA intake, serum LDL-C and CVD. However there are emerging factors in dairy foods that may reduce the risks of CVD, some are independent of blood lipid changes and others that moderate the effect of blood lipids. Notably, a recent theoretical health risk analysis⁽²²⁾ indicated that in the United States, 850 000 disability-adjusted life years (or 5.0% estimated years

of healthy life lost) due to CVD could be prevented by increased dairy food consumption. Equivalent disability-adjusted life years that may be prevented for stroke and hypertension were approximately 210 000 (6.0%) and 74 000 (5.5%), respectively⁽²²⁾.

Effects on blood pressure and haemodynamics

In the UK approximately 30% adults are estimated to be hypertensive⁽⁴⁸⁾ and hypertension is the largest single risk factor for CVD development, and stroke in particular⁽⁴⁹⁾. It is also the third biggest risk factor for premature death after smoking and poor diet. Gene polymorphisms, nutrition, the environment and interactions between these factors contribute to the development of hypertension as does advancing age and associated increased stiffness of the large arteries.

Engberink *et al.*⁽⁵⁰⁾ reported an inverse association between low-fat dairy intake and risk of hypertension in older adults; others have shown that both low- and high-fat milk products lead to hypotensive effects⁽⁵¹⁾. Also, results from the *Caerphilly prospective study* showed that when compared with non-milk drinkers, men who consumed >586 ml milk daily had on average a 10.4 mm Hg lower systolic blood pressure (SBP) after a 22.8 year follow-up⁽⁵²⁾. More recently the MEPHASOUS study⁽⁵³⁾ involving 67 011 university students showed that the risk of hypertension (classified as $\geq 140/90$ mm Hg) in highest dairy consumers was significantly and substantially reduced compared with low consumers (OR 0.15, 95% CI: 0.13, 0.18, model 4 with extensive confounders). This effect was seen in males, females, in those with normal bodyweight and those overweight or obese and despite only 6.9% students involved being classified as hypertensive. Dairy foods included milk, cheese and yoghurt although data on individual foods were not collected. The authors suggested that students often have different dietary behaviours than others and perhaps dairy replaced some sodium-rich foods/snacks. There is limited information on the effects of different dairy products on blood pressure (BP) perhaps especially normal *v.* fat-reduced types. Schmidt *et al.*⁽⁵⁴⁾ reported on a parallel design randomised controlled trial (RCT) which compared the effects of diets with low dairy, full-fat dairy and low-fat dairy in subjects with the metabolic syndrome. The results showed no effect on diastolic blood pressure, but a significant effect on SBP (*P* = 0.048), with a trend for a decrease in the low-fat dairy treatment (−1.6 (SD 8.6) mm Hg) compared with the limited-dairy diet (+2.5 (SD 8.2) mm Hg). The mean change in SBP for the full-fat dairy (−5.4 (SD 16.1) mm Hg) was not significantly different to the other two treatments indicating no adverse effect of full-fat dairy on BP.

The main milk protein types, whey protein and casein have been shown to have valuable hypotensive effects⁽⁵⁵⁾, particularly on hypertensive subjects. An 8-week RCT in mildly hypertensive volunteers⁽⁵⁶⁾ showed that whey protein isolate (2 × 28 g/d, mixed with water) had a greater hypotensive effect on 24 h ambulatory SBP (−2.0 (SEM

0.7) mm Hg) and diastolic blood pressure (-2.9 (SEM 1.1) mm Hg) than casein and the effects were seen with central and peripheral SBP. The hypotensive effect of whey protein was also seen in an acute postprandial study⁽⁵⁷⁾. A number of mechanisms involved in the hypotensive effect of milk and its components have been suggested⁽⁵⁸⁾. Peptides released during digestion of casein and whey proteins are known to have hypotensive effects by inhibiting the function of the angiotensin-I-converting enzyme leading to reduced production of the vasoconstricting angiotensin-II⁽⁵⁹⁾ which reduces its stimulation of the vasoconstrictive peptide endothelin-1. It was subsequently shown⁽⁶⁰⁾ that the Ala-Leu-Pro-Met-His-Ile-Arg peptide from β -lactoglobulin (a whey protein) was able to substantially reduce the release of endothelin-1 by pig endothelial cells. As noted earlier⁽⁵⁴⁾ there is little evidence for differential effects of low- v. high-fat dairy foods on hypertension. A recent review⁽⁶¹⁾ highlighted some inconsistencies between studies, such that some show little effect of whey protein on BP although it seems that factors including baseline BP, weight loss and obesity during the study period may influence the effect on BP⁽⁶¹⁾.

It is now understood that arterial stiffness, especially of the large vessels, is an important arterial phenotype and an excellent predictor of future CVD events⁽⁶²⁾. It is also an independent predictor of hypertension which it tends to precede and is known to be affected by diet⁽⁶³⁾. The measurement of carotid to femoral pulse wave velocity is regarded as the gold standard for estimating arterial stiffness and can directly predict CVD events⁽⁶⁴⁾. Livingstone *et al.*⁽⁵²⁾, using data from the Caerphilly prospective study following a 22.8-year follow-up, showed for the first time in a longitudinal study that dairy product consumption (not including butter) was associated with a reduced augmentation index, another valuable indicator of arterial stiffness, by 1.9% units lower ($P = 0.021$) in men with the highest dairy consumption relative to the lowest consumers. A cross-sectional study also reported that consumption of dairy foods was negatively associated with pulse wave velocity⁽⁶⁵⁾. The cross-sectional study by Ribeiro *et al.*⁽⁶⁶⁾ showed that consumption of total dairy foods was also inversely associated with carotid to femoral pulse wave velocity (-0.13 m/s) and pulse pressure (-1.3 mm Hg) with similar outcomes from consumption of low-fat dairy, fermented dairy and cheese. A systematic review and meta-analysis of cross-sectional studies⁽⁶⁷⁾ examined the effects of dairy, cheese and milk on arterial stiffness also showed that dairy foods do not have detrimental effects on pulse wave velocity. It has also been confirmed that SFA do not impair arterial stiffness in healthy subjects⁽⁶⁸⁾.

The effects of dairy foods on BP, arterial stiffness and other aspects of haemodynamics are important in the overall understanding of dairy consumption and its association with CVD risk.

Effects of dairy food matrix on blood lipids

Historically the understanding of the relationship between foods/diets and consumer health has been

based on separate assessments of the supply of energy and individual nutrients including protein, fat, carbohydrates and micronutrients. This so-called reductionist approach has given rise to incorrect concept of 'good' and 'bad' nutrients with the same for the foods they provide. Rose⁽⁶⁹⁾ suggested that this reductionist approach may explain why some research can lead to 'spurious localisation' and 'misplaced causality'. There is increasing evidence that the interactions between micro- and macrostructures of foods and their nutrients need to be taken into account as they can affect key functions such as digestion and absorption. This is the concept of the so-called food matrix. The dairy food matrix was extensively examined in 2017 by a working group organised by the Universities of Copenhagen and Reading and its findings were published⁽⁷⁰⁾. Various aspects of dairy matrix effects have been updated in more recent publications^(71–74).

Feeney and McKinley⁽⁷¹⁾ described a range of issues which link the dairy food matrix to aspects of health including CVD and bone health. To date, the best example of dairy food matrix effect is the now well-documented differential effect of hard cheese and butter when providing the same quantity of fat and SFA yet give very different blood lipid responses^(75,76). Essentially, butter leads to a predictable rise in serum total cholesterol (TC) and LDL-C, whilst the cheese generates little, none or negative LDL-C responses.

A striking example of these effects is given in the RCT of Feeney *et al.*⁽⁷⁷⁾. This was a 6-week randomised parallel design intervention with a daily intake of 40 g dairy fat within three food matrices all matched for energy, protein, fat, lactose and Ca. The matrices comprised (daily) of 120 g full-fat Irish Cheddar cheese (T1), 120 g reduced-fat Irish Cheddar cheese plus 21 g butter (T2) and 49 g butter plus 30 g calcium caseinate powder and a Ca supplement of 500 mg calcium carbonate (CaCO_3) (T3). The key results for the responses in blood lipids are given in Table 2 and clearly show the impact that the constructed matrix made to the cholesterol responses. Interestingly, these were all in a downward direction but the greater effect on the full-fat cheese was clear.

A number of mechanisms have been proposed as contributing to the possible health benefits of the hard cheese matrix but there is good evidence of cheese Ca-fatty acid soaps being synthesised in the digestive tract giving rise to increased faecal fat excretion and hence reduced fat absorbed and response in serum TC and LDL-C⁽⁷⁸⁾ and is shown in Table 3. Lorenzen and Astrup⁽⁷⁸⁾ also showed that the high dairy Ca diets also increased faecal bile acid excretion indicating reduced bile acid reabsorption in the ileum and hence less recycling back to the liver. This causes the liver to increase bile acid synthesis from cholesterol leading to a reduction in circulating cholesterol. The synthesis of Ca soaps in the digestive tract following milk consumption was shown a long time ago⁽⁷⁹⁾ and more recently confirmed in a series of *in vitro* studies⁽⁸⁰⁾. This also showed that whilst more soaps were created as the Ca:lipid ratio increased, at equal Ca:lipid ratios those dairy products with fairly solid structure (cheese) synthesised more soaps than

Table 2. Changes in blood lipids from baseline to end of 6-week intervention when 40 g/d dairy fat were provided in three types of dairy products

Blood lipid (mmol/l)	Treatment			P*
	T1	T2	T3	
Total cholesterol	-0.52 ^a	-0.37 ^{b,c}	-0.15 ^c	0.033
HDL-cholesterol	0	-0.07	+0.05	0.284
LDL-cholesterol	-0.45 ^a	-0.27 ^{b,c}	-0.14 ^c	0.016
TAG	-0.15	-0.05	-0.12	0.386

Adapted from⁽⁷⁷⁾.

T1, 120 g Irish Cheddar cheese; T2, 120 g low-fat Irish Cheddar cheese + 21 g butter; T3, 49 g butter + 30 g calcium caseinate + 500 mg calcium (as calcium carbonate (CaCO₃)) all daily.

* Overall treatment effect.

^{a,b,c} Different superscripts represent significant differences between treatments, *P* < 0.05.

milk or yoghurt with a more fluid structure. In addition there was evidence that cheese made from homogenised milk produced more soaps than from non-homogenised milk, which may be related to greater NEFA release from the homogenised milk products⁽⁸⁰⁾. This study, albeit with an *in vitro* digestion model, does increase the understanding of the Ca-fatty acid saponification process and how this may be influenced by different dairy foods.

Relatively recent findings comparing the dairy food matrix of butter and cheese on the differential effects of SFA from butter and cheese showed that the cholesterol efflux capacity (CEC) of HDL was improved in the butter treatment⁽⁴⁷⁾. This is also discussed later. Clearly, the dairy matrix in its various forms needs a more full understanding including further information on specific dairy foods, methods of cheese making, etc.

Saturated fat intake and risk of type 2 diabetes and CVD and events

As noted earlier, dairy foods are often the greatest dietary source of SFA in Western diets which has resulted in dietary guidelines recommending a restriction on dairy food consumption and/or recommending reduced fat dairy foods despite the evidence reviewed earlier. The reasoning for recommending reduced dairy fat consumption relates to the long-held view that a high intake of SFA is a critical risk factor for CVD, mainly on the

basis that SFA lead to increased blood TC and LDL-C which in turn results in the development of atherosclerosis. This apparently simple relationship is becoming increasingly questioned^(39,81–83) with recommendations that dietary guidelines should be food-based⁽⁸²⁾. In the UK it is recommended that SFA intake should be no greater than 10% total energy intake⁽⁸⁴⁾ although the UK National Diet and Nutrition Survey⁽⁸⁵⁾ clearly shows that on average, the population considerably exceeds the target. The US recommendations⁽⁸⁶⁾ also recommend no greater than 10% but the American Heart Association and American College of Cardiology Guidelines to Reduce Cardiovascular Risk have proposed reducing SFA intake to 5–6% total energy intake to moderate circulating LDL-C⁽⁸⁷⁾.

Saturated fat intake and the risk of type 2 diabetes

The possible effect of diet, and fat/fat type in particular, on T2D risk has been the subject of much interest and research over the past 25 years. Early work⁽⁸⁸⁾ created much interest as it showed that replacing SFA with MUFA significantly improved insulin sensitivity, although this was only the case for subjects with a fat intake of <37% energy intake. A subsequent review of RCT and cohort studies⁽⁸⁹⁾ showed that in five out of seven RCT, replacing SFA with MUFA or PUFA had no significant effect on insulin sensitivity although the studies were with small groups of volunteers, for short periods and involved various methods for measuring insulin sensitivity. In seven longitudinal cohort studies, four indicated that a higher SFA intake was associated with impaired insulin sensitivity although the authors emphasised that this did not prove a cause/effect relationship. Another review of both RCT and observational studies⁽⁹⁰⁾ concluded that both types of studies suggest that replacing SFA and trans fatty acids (TFA) with PUFA and/or MUFA improves insulin sensitivity and thus is likely to reduce the risk of T2D. These conclusions were however, not supported by a more recent meta-analysis of observational studies⁽⁹¹⁾ which showed no significant association between SFA and T2D although it did highlight the possible beneficial effect of ruminant TFA. The RCT by Imamura *et al.*⁽⁹²⁾ reported that replacing SFA or carbohydrate with PUFA or MUFA improved glucose-insulin homeostasis particularly in blinded studies. Overall, the effect of PUFA

Table 3. Faecal excretions resulting from the four dairy dietary treatments

Excretions	LC/HF		HC/LF		LC/LF		HC/LF		P* for effect of	
	Mean	SE	Mean	SE	Mean	SE	Mean	SE	Dairy calcium	Dairy fat
Faecal fat (g/d)	6.6	0.5	11.3	1.2	5.5	0.4	8.0	0.8	<0.0001	0.0052
Faecal calcium (mg/d)	549	34	2477	260	576	80	2478	163	<0.0001	0.9832
Faecal bile acids (μmol/d)	274	54	393	75	636	37	784	39	0.0041	0.1227
Faecal energy (kJ/d)	650	64	853	89	636	37	784	39	0.0003	0.6358

Derived from⁽⁷⁸⁾.

LC, low calcium, HC, high calcium, HF, high fat, LF, low fat; se, standard error.

* Based on two-way ANOVA.

gave the most consistent effect giving improved glycaemic control, insulin resistance and insulin secretion capacity whilst another study concluded there were too few studies on α -linolenic acid to make firm conclusions⁽⁹³⁾ although the meta-analysis of RCT by Gao *et al.*⁽⁹⁴⁾ indicated that short-term fish oil supplements were associated with improved insulin sensitivity in subjects with metabolic disorders, a conclusion supported by a review⁽⁹⁵⁾.

More recent data on any association of SFA with T2D risk were provided by the Netherlands cohort of the EPIC study⁽⁹⁶⁾ and key results are summarised in Table 4. The key conclusion was that total SFA did not relate to T2D risk as was also the case for 16:0 and 18:0 which represent the greatest amount of dietary SFA. The 12:0 and 14:0 SFA were associated with a small reduction of T2D risk but the sum of 15:0 and 17:0 was associated with a somewhat greater risk reduction. It was also noted that association may be dependent on the type of food providing the SFA with cheese-derived SFA being associated with a reduced T2D risk whilst milk and milk products were neutral (Table 4). This study⁽⁹⁶⁾ also showed that substituting SFA with unspecified animal protein (HR per 1% energy 1.12, 95% CI: 1.07, 1.17) or carbohydrates (HR per 1% energy 1.05, 95% CI: 1.02, 1.08) was associated with a significantly higher risk of T2D. Interestingly, substituting SFA with vegetable protein (HR per 1% energy 1.15, 95% CI: 1.03, 1.28) or PUFA (HR per 1% energy 1.15, 95% CI: 1.04, 1.27) was also linked to an increased risk of T2D risk although MUFA were neutral. In contrast, the systematic review and meta-analysis by Neuenschwander *et al.*⁽⁹⁷⁾ found that a high intake of vegetable fat (unspecified types) was associated with a lower T2D risk (summary RR 0.81, 95% CI: 0.76,

0.88, non-linear response $P = 0.028$) as was SFA intakes greater than about 17 g/d (summary RR 0.95, 95% CI: 0.90, 1.00, non-linear response $P = 0.023$).

Sobczak *et al.*⁽⁹⁸⁾ highlighted that 'although there is a persistent notion that SFA should be avoided' the evidence for an association of SFA with T2D is not clear and this may, at least in part, be due to a varying influence of the food supplying the SFA. They also confirmed that T2D is generally associated with higher plasma concentrations of NEFA which is also related to an increased risk of CVD⁽⁹⁸⁾. Details of the mechanisms involved in this NEFA increase are not fully understood but Sobczak *et al.*⁽⁹⁸⁾ suggest that dietary fats and changes to lipid metabolism are likely to be involved but confirm that circulating 12:0, 16:0 and 18:0, whilst firmly associated with T2D risk, are not necessarily a result of dietary intake. They suggest that the increased plasma SFA in obesity and T2D may be primarily the result of de novo lipogenesis (DNL) from excess carbohydrate. They conclude that since T2D is often linked to dyslipidaemia, including the increased plasma NEFA, emphasis should be given to how these changes can be reversed in the treatment of T2D including the role of lipid lowering drugs⁽⁹⁸⁾.

A recent study investigated the cross-sectional correlation between three dietary patterns and measures of adiposity (a key risk factor for T2D), namely BMI and waist circumference, in 1280 adults from seven European countries in the Food4Me study⁽⁹⁹⁾. They also looked at any interaction effects of the obesity-associated *FTO* gene. They concluded that a dietary pattern high in SFA and discretionary foods and drinks, and low in fibre, was associated with an increased risk of overall and central obesity. It seems possible that diets high in SFA and discretionary foods would also be high in total fat and the

Table 4. Multivariable hazard ratios (HR) with 95% confidence intervals for the associations between the intakes of total SFA, individual SFA and food sources of SFA with incidence of type 2 diabetes in EPIC Netherlands study⁽⁹⁶⁾

	Median intake (% EI/d)	Model 4* HR (95% confidence interval)	Model 5† HR (95% confidence interval)
Total SFA			
Total SFA per 1% EI	14	0.96 (0.93, 0.99)	0.97 (0.94, 1.00)
Total SFA per g	32 g/d	0.99 (0.98, 1.01)	1.00 (0.98, 1.01)
Individual SFA			
Lauric acid (12:0)	0.63	0.89 (0.83, 0.97)	0.92 (0.85, 0.99)
Myristic acid (14:0)	1.51	0.78 (0.70, 0.87)	0.89 (0.79, 0.99)
Pentadecylic acid (15:0)	0.08	0.79 (0.71, 0.88)	0.90 (0.80, 1.00)
Palmitic acid (16:0)	1.22	0.95 (0.84, 1.08)	0.90 (0.80, 1.03)
Margaric acid (17:0)	0.16	0.76 (0.66, 0.87)	0.84 (0.73, 0.97)
Stearic acid (18:0)	3.47	1.01 (0.90, 1.12)	0.92 (0.83, 1.03)
Sum of 4:0 to 10:0 acids	0.67	0.86 (0.79, 0.94)	0.93 (0.85, 1.01)
Sum 15:0 and 17:0 acids	0.37	0.78 (0.69, 0.87)	0.88 (0.79, 0.99)
Food sources of SFA			
Cheese	2.33	0.86 (0.79, 0.93)	0.90 (0.83, 0.98)
Milk/milk products	2.30	0.96 (0.89, 1.04)	1.01 (0.93, 1.10)
Meat	2.53	1.10 (1.02, 1.19)	1.03 (0.95, 1.11)

EI, energy intake.

* Adjustments for total energy intake, sex, age, education level, energy-adjusted alcohol consumption level, smoking status, physical activity level, energy-adjusted intake of animal protein, vegetable protein, trans fatty acids, vitamin E, dietary fibre and cholesterol.

† Additional adjustments for BMI and waist circumference.

higher energy density was responsible for the increased adiposity rather than a specific functional effect of SFA. They also showed that whilst the *FTO* genotype was linked with an increased risk of obesity, there was no genotype \times dietary pattern interaction⁽⁹⁹⁾.

Overall, the association of dietary SFA with T2D risk is mixed, although with some tendency for replacing SFA with MUFA/PUFA being associated with improved insulin sensitivity^(96,98). In addition, it may be that the risk is influenced by the food providing the SFA as suggested by the generally beneficial association between dairy foods and T2D risk noted earlier. It does also seem that more detail is needed on the role of the DNS/carbohydrate pathway in reducing the risk and treatment of T2D.

Saturated fat intake and the risk of CVD

Evidence from prospective cohort studies

The meta-analysis of twenty-one prospective cohort studies involving 347 747 subjects reported that SFA were not associated with an increased risk of CHD (RR 1.07, 95% CI: 0.96, 1.19), CVD (RR 1.00, 95% CI: 0.89, 1.11) or stroke (RR 0.81, 95% CI: 0.62, 1.05)⁽¹⁰⁰⁾. The authors commented that their meta-analysis identified that there was still insufficient evidence from prospective studies to conclude that dietary SFA is associated with an increased risk of CHD, stroke or overall CVD. The meta-analysis by Chowdhury *et al.*⁽¹⁰¹⁾ involved thirty-two observational studies with fatty acid intakes and seventeen observational studies with circulating fatty acids. The RR for CHD comparing the highest *v.* lowest SFA intake was neutral (RR 1.03, 95% CI: 0.98, 1.07). A similar neutrality was observed for MUFA and *n*-6 PUFA whilst long-chain *n*-3 PUFA were associated with a reduced risk (RR 0.87, 95% CI: 0.78, 0.97)⁽¹⁰⁰⁾. A meta-analysis of twelve prospective cohorts also raised doubts about the validity of SFA being linked with increased CVD risk⁽⁹¹⁾. They found no association between SFA intake and ACM, CVD mortality or ischaemic stroke but perhaps strangely, reported 'no convincing lack of association' between SFA and CHD mortality (RR 1.15, 95% CI: 0.97, 1.36, *P* = 0.10).

The primary findings of the PURE study⁽⁴⁰⁾ in relation to SFA intake are summarised in Table 5 and indicate that increasing intake of SFA was associated with a

significantly reduced risk of total mortality, stroke and non-CVD mortality but had no association with major CVD events, MI or CVD mortality. Increased intakes of MUFA and PUFA were also associated with a reduced risk of total mortality although carbohydrate intake was associated with an increased risk of ACM but not risk of CVD or CVD mortality. The relationships of SFA intake and blood lipids in the PURE study showed that whilst increased SFA intake raised serum TC and LDL-C it also increased HDL-cholesterol (HDL-C) leading to a lower TC:HDL-C ratio, both associated with a reduced CVD risk in support of the observed reduction in ACM and stroke⁽¹⁰²⁾. In addition, serum TAG declined with increasing SFA intake also associated with a lower CVD risk. The key implication of these findings is that the use of either TC or LDL-C as CVD risk markers would lead to an incorrect prediction of CVD-related risk⁽⁸¹⁾. It should be noted that dietary evidence was only obtained at baseline, and overall average total SFA intake was low which may limit widespread applicability.

More recently an umbrella study of nine meta-analyses of prospective studies (a total of 147 studies with about 3.1 million subjects) was published⁽¹⁰³⁾. All but two of the meta-analyses showed that SFA intake was not associated with CHD, whilst two found that replacing SFA with PUFA was associated with a reduced risk of CHD although the overall conclusion from the study was that the meta-analysis of observational studies found no association between SFA intake and CHD⁽¹⁰³⁾.

Mazidi *et al.* studied the associations between quartiles of total fat, SFA, MUFA and PUFA consumption on the risks for ACM, CHD and stroke-related mortality in 24 144 subjects in the National Health and Nutrition Examination Surveys 1999–2010⁽¹⁰⁴⁾. In addition, they included data from their own study leading to a meta-analysis based on studies published by November 2018. Based on fully adjusted Cox-proportional hazard models in the National Health and Nutrition Examination Surveys prospective study, there were inverse associations between intake (quartile 4 *v.* quartile 1) of total fat (HR, 0.90, 95% CI: 0.82, 0.99) and PUFA (HR 0.81, 95% CI: 0.78, 0.84) with ACM, whilst SFA intake were associated with slightly increased mortality (HR 1.08, 95% CI: 1.04, 1.11). These results are from the fully adjusted models (two) which adjusted for serum non-HDL-C and dietary cholesterol although it

Table 5. Association between percentage energy intake from SFA and clinical outcomes in the PURE study⁽⁴⁰⁾

	Hazard ratio (HR, 95% confidence interval) <i>v.</i> quintile 1					<i>P</i> trend
	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5	
% Energy from SFA*	2.8	4.9	7.1	9.5	13.2	
Total mortality	Reference	0.96 (0.88, 1.05)	0.92 (0.83, 1.02)	0.85 (0.75, 0.95)	0.86 (0.76, 0.99)	0.0088
Major CVD events	Reference	1.13 (1.02, 1.25)	1.06 (0.95, 1.18)	1.03 (0.91, 1.17)	0.95 (0.83, 1.10)	0.49
Myocardial infarction	Reference	1.28 (1.08, 1.51)	1.20 (1.00, 1.44)	1.16 (0.95, 1.41)	1.17 (0.94, 1.45)	0.40
Stroke	Reference	1.10 (0.97, 1.25)	1.01 (0.87, 1.17)	0.93 (0.78, 1.11)	0.79 (0.64, 0.98)	0.0498
CVD mortality	Reference	1.04 (0.87, 1.24)	0.95 (0.78, 1.17)	0.99 (0.79, 1.23)	0.83 (0.65, 1.07)	0.20
Non-CVD mortality	Reference	0.94 (0.84, 1.04)	0.91 (0.81, 1.03)	0.78 (0.68, 0.91)	0.86 (0.73, 1.01)	0.0108

* Median of each quintile.



is not known what, if any, effect these had. The meta-analysis involving twenty-nine prospective cohorts (about 1.2 million subjects) showed an inverse association between intake of total fat (HR 0.89, 95% CI: 0.82, 0.97), MUFA (HR 0.94, 95% CI: 0.89, 0.99) and PUFA (HR 0.89, 95% CI: 0.84, 0.94) with ACM, although SFA showed no significant association (HR 1.05, 95% CI: 0.99, 1.12). No association was seen for total fat (HR 0.93, 95% CI: 0.80, 1.08) and SFA (HR 0.93, 95% CI: 0.80, 1.08) with CVD mortality. Total fat had no association with CHD mortality (HR 1.03, 95% CI: 0.99, 1.09) whereas SFA had a positive association with CHD mortality (HR 1.10, 95% CI: 1.01, 1.21). Neither MUFA nor PUFA intakes were associated with CVD or CHD mortality but both had inverse associations with stroke mortality (MUFA HR 0.80, 95% CI: 0.67, 0.96; PUFA HR 0.84, 95% CI: 0.80, 0.90). No association was seen for SFA and stroke mortality. As the authors mention, single-nutrient studies are complicated by the fact that changes in one may affect another. As a result it is not known if increased MUFA and PUFA intake replaced SFA or whether all were independent changes which could influence the interpretation. This study does add to the limited data on the beneficial association of MUFA with CVD-related mortality and indicates a limited association of SFA with the range of CVD-related outcomes studied⁽¹⁰⁴⁾.

An additional meta-analysis with nineteen cohort studies (about 1 million subjects) has been reported recently⁽¹⁰⁵⁾. Overall, this reported a non-linear association between SFA and ACM and CVD mortality with the risk increasing up to an SFA intake of 11% energy intake followed by a plateau or slightly reducing risk. A sub-group analysis which included adjustments for fat intake and serum lipids did not change the associations. Significant inverse associations with ACM were seen for MUFA and PUFA intakes. A scoping study of forty-four systematic reviews of prospective studies mostly on highest *v.* lowest exposure to dietary fat/fat types on health outcomes was reported⁽¹⁰⁶⁾. Overall, this mainly found no association of total fat, MUFA and/or PUFA and SFA with risk of CVD and CHD, and SFA had no association with ACM and a negative association with risk of stroke. This study⁽¹⁰⁶⁾ also included a scoping study of RCT which is discussed in the next section.

The evidence from prospective studies on the association of SFA with mortality and CVD events is mixed although most studies/meta-analyses^(40,91,100,101,103,104,106) reported a neutral or negative association. The PURE study^(40,102) is of particular interest as it also provided data on blood lipids, with increased SFA intake increasing serum TC and LDL-C but also increased in HDL-C leading to a reduction in the TC:HDL-C ratio, in agreement with the observed reduction in ACM and stroke. This study indicates that intake of SFA is not a good predictor of CVD risk and that the use of LDL-C as a risk factor in isolation may also be misleading.

Whilst prospective studies are usually regarded as providing less valuable evidence than from RCT, they do

have merits including large subject numbers, long study periods, ability to study foods, not just nutrients and hard clinical outcomes. Generally, they cannot prove cause and effect for which RCT are needed. Nevertheless, as recently highlighted^(83,107), the evidence that prospective studies provide should be seriously considered when dietary guidelines are set as the simple 'diet-heart hypothesis is now of uncertain validity'⁽¹⁰⁷⁾.

Evidence from randomised controlled trials

The Sydney heart study and the Minnesota Coronary Experiment were carried out in the period 1966–1973 but have been reanalysed more recently with more up to date statistical techniques^(108,109). Both were long-term (Sydney median follow-up 39 months; Minnesota ≥ 12 months) RCT examining the replacement of dietary SFA with linoleic acid-rich PUFA on CVD events and mortality. The Sydney study⁽¹⁰⁸⁾ reported the PUFA intervention group to have significantly higher ACM rates (HR 1.31, 95% CI: 1.06, 1.58) than the SFA-rich control (HR 0.70, 95% CI: 0.53, 0.91) despite the PUFA treatment leading to a greater reduction in blood TC. Similarly, the Minnesota study⁽¹⁰⁹⁾ showed that the PUFA treatment led to significant reductions in TC but this did not lead to a reduction in mortality relative to the SFA-rich control.

Broadly, these two RCT appeared to contradict the traditional diet-heart hypothesis such that whilst SFA replacement led to reductions in TC (and presumably LDL-C which was not reported), these did not lead to reduced mortality. There are however substantial concerns about the value of these studies, including whether the subjects (70% smokers in Sydney), the settings (psychiatric hospitals and nursing homes) and the diets used are relevant to contemporary populations. Also, a major concern is the fact that both studies used margarines and related products, which in the period of the studies, were rich sources of industrial TFA which were not measured but could have influenced the findings considerably.

The evidence from ten meta-analyses published from 2010 to 2017 was included in a narrative umbrella review of RCT⁽¹⁰³⁾. No evidence was seen of a significant increase in CHD mortality or total mortality related to SFA intake, although three analyses showed reductions in CHD/CVD disease events linked with replacing SFA with PUFA. Heileson⁽¹⁰³⁾ also reviewed the strengths and weaknesses of this set of analyses and identified high between-study heterogeneity and highlighted that some key confounding variables such as changes in TFA and *n*-3 fatty acids and potential bias from lack of blinding, made collective interpretation of the results difficult. The overall conclusion was that SFA are not independently linked to heart disease, and despite leading to reductions in LDL-C, replacing SFA with PUFA may not be beneficial. This review was also critical of the proposal to replace SFA with PUFA by the Presidential Advisory paper from the American Heart Association⁽¹¹⁰⁾ as it was felt that the studies used had many design faults and omitted consideration of possible interference by TFA in high-PUFA treatments.



The recent updated Cochrane review and meta-analysis⁽¹¹¹⁾ assessed the effects of replacing SFA energy intake with carbohydrate, PUFA, MUFA and/or protein on mortality and CVD-related morbidity with data from fifteen RCT (involving sixteen comparisons) that met strict inclusion criteria and totalled almost 60 000 subjects. Interestingly, the Sydney heart study was included but the Minnesota Coronary Experiment was excluded due to its short mean follow-up period. The key results from this meta-analysis were that reductions in dietary SFA had little or no effect on ACM, CVD-related mortality, non-fatal MI and CHD mortality. The findings on total (fatal or non-fatal) MI, stroke and CHD events (fatal or non-fatal) were reported to be unclear due to very low-quality data. The meta-analysis did however find that reducing dietary SFA for at least 2 years led to a significant 21% reduction in combined CVD events although this was not linked to the risk of CVD-related mortality. Of note is that only three studies were included in the at least 2 years study duration subgroup and there was no significant effect of SFA reduction on CVD events in the up to 24 months, and longer than 48 months subgroups. Overall, no significant differences were found between the replacement of SFA energy with that from PUFA or carbohydrates whilst data on energy replacement by MUFA and protein were extremely limited⁽¹¹¹⁾.

This meta-analysis also examined the effect of SFA reduction on changes in serum cholesterol. For the studies with suitable data, TC and LDL-C had mean changes of -0.24 (95% CI: $-0.36, -0.13$) mmol/l and -0.19 (95% CI: $-0.33, 0.05$) mmol/l, respectively, with the greatest reductions seen with replacement by PUFA. Perhaps surprising, only one study with replacement by MUFA was available for TC change and none for LDL-C change. There were no or very limited changes in HDL-C and lipoprotein(a). The observed changes in TC were not related to the primary outcomes of ACM and CVD mortality and TC reduction was only related to CVD events when the reduction was at least 0.2 mmol/l, but this may be important. For secondary outcomes of stroke and non-fatal MI, changes in TC had no significant relationship, but like CVD events, TC reductions of at least 0.2 mmol/l were associated with a lower risk of all MI (fatal and non-fatal) events, but it must be remembered that the evidence quality for MI outcomes was GRADE low and very low.

A scoping study of fifteen RCT showed that isoenergetic replacement of carbohydrate by SFA increased blood TC, LDL-C and HDL-C but reduced TAG⁽¹⁰⁶⁾. Replacement of carbohydrate by MUFA and PUFA reduced TC, LDL-C and TAG but increased HDL-C. It was concluded overall, that whilst prospective studies (see previous section) found little or no associations of SFA, MUFA, PUFA with CVD or ACM, the evidence from RCT showed that replacement of SFA with MUFA and/or PUFA generally improved blood lipids and glycaemic control. On this basis it was concluded that current recommendations to replace SFA with MUFA/PUFA should be retained. As discussed earlier and later, reductions in blood lipids, notably LDL-C,

do not always lead to the often assumed reduction in CVD risk.

Overall, the findings from RCT broadly agree with the conclusions from the prospective cohort studies that the traditional diet-heart hypothesis may not always be valid.

Are all SFA equal in relation to type 2 diabetes and CVD?

Results from the EPIC-InterAct case-cohort study with 12 132 cases of T2D showed that different plasma phospholipid SFA were independently associated with incident T2D in opposite directions⁽¹¹²⁾. Odd-chain SFA 15:0 and 17:0 and long-chain SFA 20:0, 22:0, 23:0 and 24:0 were inversely associated whilst even-chain 14:0, 16:0 and 18:0 were positively associated. The negative association of plasma phospholipid 15:0 and 17:0 with T2D risk was seen in women but not in men in the EPIC-Potsdam cohort⁽¹¹³⁾. Both studies highlighted the role of dairy products as exogenous sources of odd-chain SFA, giving support to prospective studies which showed negative associations between dairy consumption and T2D.

Two recent studies^(114,115) highlighted the risks of assuming that plasma and tissue palmitic acid (16:0) concentrations are simply a reflection of its dietary intake since some palmitic acid is synthesised by the DNL pathway, primarily from carbohydrate with some from protein and alcohol. Palmitic acid can be elongated to 18:0 (stearic acid) and desaturated to palmitoleic acid (16:1n-7) and 18:0 can be desaturated to 18:1n-9 (oleic acid). In healthy subjects rather limited DNL occurs primarily in adipose tissue although certain conditions including insulin resistance and a high dietary intake of carbohydrates, particularly sugars, enhance hepatic DNL substantially, contributing to hyperlipidaemia⁽¹¹⁶⁾. This is supported by studies showing that replacing dietary SFA with refined carbohydrates is associated with an increased risk of CVD⁽¹¹⁷⁾. A pooled analysis of seventeen prospective cohorts showed that all four DNL-related fatty acids were positively associated with incident T2D with RR of the highest v. lowest plasma concentrations being 1.53 (95% CI: 1.41, 1.66; $P < 0.001$) for 16:0, 1.40 (95% CI: 1.33, 1.48; $P < 0.001$) for 16:1n-7, 1.14 (95% CI: 1.05, 1.22; $P = 0.001$) for 18:0 and 1.16 (95% CI: 1.07, 1.25; $P < 0.001$) for 18:1n-9⁽¹¹⁴⁾. Murru *et al.*⁽¹¹⁵⁾ concluded that blaming a single nutrient such as 16:0, which has recognised physiological actions, and proposing that reducing its dietary intake in order to reduce CVD is too simplistic. They proposed that population guidelines should not be based on single nutrients but consideration of the whole diet. However the role of DNL in the aetiology of T2D would seem to require considerably more investigation.

Others have also highlighted some of the weaknesses associated with simply looking at the effects of total SFA without considering the possible effects of individual SFA. Dawczynski *et al.*⁽¹¹⁸⁾ assessed the



meta-analysis of Chowdhury *et al.*⁽¹⁰¹⁾ and showed that two of the eight studies used in relation to the CVD risk associated with SFA included 15:0 and 17:0 fatty acids in serum phospholipids which are primarily a marker for intake of milk fat. Dairy products in general are known to have neutral or negative associations with CVD risk (Table 1) and it was proposed that these two studies should not have been included in the meta-analysis. Dawczynski *et al.*⁽¹¹⁸⁾ reanalysed the data after the exclusion of these two studies which then produced a positive association of total SFA concentration in blood and coronary events (RR 1.21, 95% CI: 1.04, 1.40) confirming the importance of not including 15:0 and 17:0 along with other SFA. As noted earlier these odd-chain SFA have also been shown to have a negative association with T2D suggesting that detailed knowledge of the contributions of specific foods to CVD and T2D risk is important.

SFA–cholesterol–CVD risk relationship

For some considerable time, LDL-C concentration in serum/plasma has been measured to predict the risk of CVD. There is consistent evidence that most SFA increase LDL-C and HDL-C⁽¹¹⁹⁾ and that LDL particles have a causative role in the development of atherosclerotic CVD⁽¹²⁰⁾. There is however increasing uncertainty that lowering LDL-C concentration by reducing dietary SFA intake will inevitably lead to a CVD risk reduction^(40,102). There are a number of possible reasons for this.

Is LDL-cholesterol a valid predictor of CVD risk?

The TC:HDL-C ratio has been found to provide a better estimate of CVD risk than LDL-C alone⁽¹²¹⁾ due, at least in part, to its relationship with LDL particle number⁽¹²²⁾. For this reason and as proposed⁽¹²¹⁾ TC:HDL-C should be used to provide additional clinical information to LDL-C in primary prevention especially in high-risk patients. It has also been highlighted that there can be considerable variation in serum LDL-C response to SFA intake between individuals and this may contribute to the uncertainty of the SFA–CVD risk relationship⁽¹²³⁾. Griffin *et al.*⁽¹²³⁾ identified a number of metabolic and genetic reasons for this variation and suggested that a blood biomarker of serum LDL-C responsiveness to SFA replacement would improve the estimation of CVD risk. Recently it has also been shown that substantial between-subject responses occurred in TC and LDL-C in subjects who consumed about 40 g dairy fat/d either as butter, cheese or reduced-fat cheese plus butter⁽¹²⁴⁾. They showed that the percentage of change in TC and LDL-C was associated with baseline TC, TAG, body weight and high-sensitivity C-reactive protein. These studies again show an uncertainty in the reliance on LDL-C as a single useful CVD risk predictor.

Role of LDL particle size and density

Another limitation of using LDL-C as a single predictor of CVD risk, relates to the fact that LDL-C contains the

cholesterol present in all LDL particles. Yet the small, dense LDL particles, although containing less cholesterol per particle than the large, more buoyant LDL particles, are generally agreed to be more strongly associated with increased atherosclerosis^(125,126). To some extent this has been challenged by the Ludwigshafen risk and cardiovascular health study⁽¹²⁷⁾. This showed for the first time, in 1643 patients referred for coronary angiography and followed up for a median of 9.9 years, that both large and small LDL particles were independently associated with an increased risk of ACM and CVD mortality (small LDL: HR 1.50, 95% CI: 1.06, 2.12, $P=0.021$; large LDL: HR 1.89, 95% CI: 1.32, 2.70, $P<0.001$, both from model 3) compared with particles of intermediate size⁽¹²⁷⁾. Perhaps contributing to the findings, patients with small LDL also had higher concentrations of oxidised LDL and those with buoyant LDL had higher concentrations of the inflammatory markers IL-6 and C-reactive protein than those with intermediate LDL, although the reason for the latter was not known. The significance of this study against the background of evidence confirming the higher risk associated with small-dense LDL⁽¹²⁸⁾ is unclear.

A number of studies have demonstrated that SFA tends to increase the large, buoyant LDL possibly contributing to the reason why some studies^(108,109) have not shown a reduction in risk of CVD and/or mortality when SFA are replaced by PUFA/MUFA. The RCT by Bergeron *et al.*⁽¹²⁹⁾ compared diets with high-SFA (about 13–14% energy intake) with low-SFA diets (about 7–8% energy intake) which had SFA replaced with MUFA with the differences in SFA content between the high- and low-SFA treatments being achieved mainly by using high-fat dairy foods and butter. There was no significant difference in plasma HDL-C between the two treatments but whilst the high-SFA diet increased plasma LDL-C, this was due entirely to a significant rise in large LDL particles (about 577 v. 542 nmol/l) with no differences in medium, small or very small LDL particles⁽¹²⁹⁾. This suggests that the effect of SFA from red meat, white meat and dairy (which were used in the diets) on LDL-C could be moderated by the rise in large LDL particles but not small, dense particles. A recent valuable narrative review⁽¹²⁸⁾ examined the evidence from twenty-eight RCT on the effects of fat and fat type on the resulting LDL particle size profile. Overall, it was shown that consuming diets of higher fat and SFA contents led to increased large, buoyant LDL particles and/or a reduction in small LDL particles. A key conclusion was that LDL particle size is primarily affected by high- v. low-fat and high- v. low-SFA diets, although it was emphasised that more work was needed on the effects of individual SFA and the need to consider overall dietary patterns, notably plant-based v. animal-based diets⁽¹²⁸⁾. Nevertheless, these findings may at least partly explain why high-SFA dairy foods are not associated with increased CVD risk, although an RCT involving subjects consuming SFA-reduced, MUFA-enriched (modified) milk, cheese and butter, compared with conventional counterparts, found that whilst the modified foods led to a significantly reduced serum

LDL-C response, there were no significant differences in the proportions of small, medium and large LDL particles between dietary treatments⁽¹³⁰⁾. The impact of the food matrix in various dairy foods on LDL subtypes clearly needs exploration.

In relation to dairy foods, it is of note that a cross-sectional study in 291 healthy Swedish men indicated that dietary fatty acids typically found in dairy foods were associated with less small-dense LDL particles⁽¹³¹⁾. In particular, SFA 4:0 to 10:0 and 14:0 ($P < 0.05$) in the diet and 15:0 and 17:0 (markers of dairy fat intake) in serum phospholipids ($P < 0.05$) were associated with fewer small-dense LDL particles. This study suggested that LDL particle size distribution may be favourably modified by dairy products in the diet, or that other dietary SFA have a detrimental effect and milk SFA attenuate this effect rather than have a positive effect themselves.

Effect of food source of SFA

There is now some evidence that the effect of SFA can depend on the food source. Two prospective studies found that whilst a positive association with CVD risk was seen with SFA from meat, this was not the case for SFA from dairy^(76,132). A study in a Dutch population with a relatively high intake of SFA from dairy foods showed an inverse association between SFA intake and IHD risk which was primarily driven by SFA from dairy foods (including short- to medium-chain SFA, 14:0 and the sum of 15:0 and 17:0), whilst those from other sources (including meat) were essentially neutral⁽¹³³⁾.

A systematic review and dose-response meta-analysis of 123 prospective studies on the associations between food groups and the risk of CHD, stroke and heart failure was reported by Bechthold *et al.*⁽¹³⁴⁾. This showed that dairy food intake was not associated with risk of CHD (RR 0.99, 95% CI: 0.92, 1.07), stroke (RR 0.96, 95% CI: 0.90, 1.01) or heart failure (RR 1.00, 95% CI: 0.90, 1.10) whilst red, and especially processed meat, were significantly and positively associated with an increased risk of all three disease outcomes. There was little discussion on the relative effects of SFA from the different food groups, but it was stated that the role of SFA in relation to CVD health is 'controversial'⁽¹³⁴⁾.

These observations may be related to food-specific fatty acids or other aspects of the foods including their matrix, but clearly detailed RCT are needed to resolve the reasons for these differential effects.

Functionality of HDL-cholesterol

For the general population there is good evidence that serum HDL-C concentration is inversely associated with CVD and mortality⁽¹³⁵⁾ leading to the use of the TC:HDL-C ratio as an improved predictor of CVD risk, based on low HDL-C concentration being associated with increased CVD risk⁽¹³⁶⁾. However it has been reported that men and women with extremely high-serum HDL-C concentrations (>1.9 mmol/l, 95% CI: 1.4, 2.0; >2.4 mmol/l, 95% CI: 1.8, 2.5, for men and

women, respectively) also have high mortality⁽¹³⁷⁾ which challenges the use of the TC:HDL-C ratio. Moreover, drug treatments to raise HDL-C have not been associated with reduced ACM, CHD mortality, MI or stroke⁽¹³⁸⁾. However SFA can increase HDL-C, particularly when they replace carbohydrates⁽⁴⁷⁾, and SFA from butter, but not cheese, have also been shown to increase the CEC of HDL in men but not women, although interestingly, the same study showed that MUFA increased the CEC of HDL in women but not men⁽⁴⁷⁾. This led Griffin and Lovegrove⁽¹³⁹⁾ to question whether the increased CEC of HDL is in some way a compensation for the increased LDL-C following butter consumption. The study by Brassard *et al.*⁽⁴⁷⁾ confirmed that the effect of SFA on the LDL-C/HDL-C mediated risk of CVD depends on the food source and possibly the sex of the consumer. However, this and the study by Madsen *et al.*⁽¹³⁷⁾ highlight the need for further research to clarify whether HDL-C truly has a CVD protective role.

Overall, despite LDL particles having a causal role for atherosclerotic CVD⁽¹²⁰⁾, there is now evidence that changes in serum LDL-C concentrations alone may not reliably predict future atherosclerotic CVD risk. Whilst the TC:HDL-C ratio may have benefits over LDL-C alone, the facts that the CVD protective effect of HDL-C now seems less certain, the CEC of HDL can vary, SFA tend to increase the less atherogenic large LDL particles and SFA from different foods can have contrasting effects on CVD risk, all cast doubt on the validity of the classical SFA leading to increased LDL-C and hence an increased risk of CVD relationship. This may also explain at least some of reasons that high-SFA dairy foods are not associated with CVD risk. Additional validated risk markers are therefore needed with assessment of vascular endothelial function⁽¹³⁰⁾ and broader vascular function⁽⁶¹⁾ being potentially valuable non-blood lipid targets.

Conclusions

Overall, the prospective studies and RCT included in this review show that SFA from dairy foods are not generally associated with T2D risk, although the consistent inverse association between yoghurt consumption and T2D, together with the increasing prevalence of T2D, means that this is potentially very important. Whilst some mechanisms have been proposed to support this association, more research is needed to improve the evidence which would lead to a better understanding of the type and amount of yoghurt needed for maximum benefit. The association between dairy foods and CVD is generally neutral despite many of the dairy foods being the major source of SFA in many diets. This leads to substantial doubt concerning the validity of the traditional diet-heart hypothesis which positively relates increased SFA intake to increased serum cholesterol and subsequent increased CVD. Studies that included serum cholesterol measurements broadly agree with the positive relationship between SFA intake and LDL-C

concentration, but without a consistent subsequent relationship with increased CVD risk, despite LDL being a causal factor in atherosclerotic CVD. There is now some emerging evidence to explain this which is highly relevant to dairy foods. These include the potentially counterbalancing effect of any SFA-stimulated HDL-C, food matrix factors, notably in hard cheese, which reduce fat absorption and moderate increased LDL-C. Other evidence includes SFA being associated with the less atherogenic large buoyant LDL particles and possible counterbalancing hypotensive action of dairy proteins.

Many parts of this emerging evidence are not fully understood or confirmed in adequately powered studies but do point to a need for a more food-based dietary recommendations and a number of respected groups have provided convincing arguments for this and not by simple limits on SFA intake^(82,140). Direct or consequential restrictions on dairy food consumption do not seem warranted but there is clear need to better understand the association of the different dairy food types with chronic diseases, particularly for T2D.

Acknowledgements

This review is based primarily on an invited presentation at the UK and Ireland Nutrition Society annual conference in July 2022. I am grateful to the Nutrition Society and members for the invitation and their support for the present paper.

Financial Support

Whilst there was no specific funding for the writing of this review, the author is supported by the University of Reading.

Conflict of Interest

The author has received travel expenses and honoraria in connection with lectures and meetings from the Dairy Council (now Dairy UK), Dutch Dairy Association, European Dairy Association and the International Dairy Federation. He has also been a consultant to the Estonian Bio-competence Centre of Healthy Dairy Products (BioCC), and to the Dairy Council on fats in dairy products and cardiometabolic diseases.

Authorship

The author had sole responsibility for preparation of the present paper.

References

1. Goodall R, Alazawi R, Hughes W *et al.* (2021) Trends in type 2 diabetes mellitus disease burden in European Union countries between 1990 and 2019. *Sci Rep* **11**, 15356.

2. Diabetes UK (2022) Cost of diabetes. <https://www.diabetes.co.uk/cost-of-diabetes.html> (accessed September 2022).
3. McEwen LN, Lee PG, Backlund J-YC *et al.* (2018) Recording of diabetes on death certificates of decedents with type 1 diabetes in DCCT/EDIC. *Diabetes Care* **41**, e158–e160.
4. Abdul-Ghani M, DeFronzo RA, Del Prato S *et al.* (2017) Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived? *Diabetes Care* **40**, 813–820.
5. Sanders TAB (2016) How important is the relative balance of fat and carbohydrate as sources of energy in relation to health? *Proc Nutr Soc* **75**, 147–153.
6. Office for National Statistics (2022) Leading causes of death, UK: 2001 to 2018. <https://www.ons.gov.uk/people-populationandcommunity/healthandsocialcare/causesof-death/articles/leadingcausesofdeathuk/2001to2018#uk-leading-causes-of-death-data> (accessed May 2022).
7. European Heart Network (2017) European cardiovascular disease statistics 2017. <https://ehnhheart.org/cvd-statistics/cvd-statistics-2017.html> (accessed May 2022).
8. Pereira MA, Jacobs Jr DR, Van Horn L *et al.* (2002) Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA study. *JAMA* **287**, 2081–2089.
9. Elwood PC, Pickering JE & Fehily AM (2007) Milk and dairy consumption, diabetes and the metabolic syndrome: the Caerphilly prospective study. *J Epidemiol Community Health* **61**, 695–698.
10. van Meijl LE, Vrolix R & Mensink RP (2008) Dairy product consumption and the metabolic syndrome. *Nutr Res Rev* **21**, 148–157.
11. Tong X, Dong J-Y, Wu Z-W *et al.* (2011) Dairy consumption and risk of type 2 diabetes mellitus: a meta-analysis of cohort studies. *Eur J Clin Nutr* **65**, 1027–1031.
12. Gao D, Ning N, Wang C *et al.* (2013) Dairy products consumption and risk of type 2 diabetes: systematic review and dose–response meta-analysis. *PLoS ONE* **8**, e73965.
13. Aune D, Norat T, Romundstad P *et al.* (2013) Dairy products and the risk of type 2 diabetes: a systematic review and dose–response meta-analysis of cohort studies. *Am J Clin Nutr* **98**, 1066–1083.
14. Imamura F, Fretts A, Marklund M *et al.* (2018) Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: a pooled analysis of prospective cohort studies. *PLoS Med* **15**, e1002670.
15. Mozaffarian D, de Oliveira Otto MC, Lemaitre RN *et al.* (2013) *trans*-Palmitoleic acid, other dairy fat biomarkers, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Clin Nutr* **97**, 854–861.
16. Guo J, Givens DI, Astrup A *et al.* (2019) The impact of dairy products in the development of type 2 diabetes: where does the evidence stand in 2019? *Adv Nutr* **10**, 1066–1075.
17. Soedamah-Muthu SS & de Goede J (2018) Dairy consumption and cardiometabolic diseases: systematic review and updated meta-analyses of prospective cohort studies. *Curr Nutr Rep* **7**, 171–182.
18. Drouin-Chartier J-P, Li Y, Korat AVA *et al.* (2019) Changes in dairy product consumption and risk of type 2 diabetes: results from 3 large prospective cohorts of US men and women. *Am J Clin Nutr* **110**, 1201–1212.
19. Companys J, Pla-Pagà L, Calderón-Pérez L *et al.* (2020) Fermented dairy products, probiotic supplementation, and cardiometabolic diseases: a systematic review and meta-analysis. *Adv Nutr* **11**, 834–863.

20. Wuni IR, Lakshmipriya N, Abirami K *et al.* (2022) Higher intake of dairy is associated with lower cardiometabolic risks and metabolic syndrome in Asian Indians. *Nutrients* **14**, 3699.
21. Fernandez M, Panahi S, Daniel N *et al.* (2017) Yogurt and cardiometabolic diseases: a critical review of potential mechanisms. *Adv Nutr* **8**, 812–829.
22. Cohen SS, Bylsma LC, Movva N *et al.* (2022) Theoretical attributable risk analysis and disability adjusted life years (DALYs) based on increased dairy consumption. *BMC Public Health* **22**, 1625.
23. Jackman SR, Witard OC, Philp A *et al.* (2017) Branched-chain amino acid ingestion stimulates muscle myofibrillar protein synthesis following resistance exercise in humans. *Front Physiol* **8**, 390.
24. Gorissen SHM & Witard OC (2018) Characterising the muscle anabolic potential of dairy, meat and plant-based protein sources in older adults. *Proc Nutr Soc* **77**, 20–31.
25. Market Analysis Report (2022) Whey protein market size, share & trends analysis report by type (whey protein isolates, whey protein concentrates, whey protein hydrolysates), by application, by region, and segment forecasts, 2020–2027. <https://www.grandviewresearch.com/industry-analysis/whey-protein-market> (accessed September 2022).
26. Wang TJ, Larson MG, Vasan RS *et al.* (2011) Metabolite profiles and the risk of developing diabetes. *Nat Med* **17**, 448–453.
27. Guasch-Ferré M, Hruby A, Toledo E *et al.* (2016) Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. *Diabetes Care* **39**, 833–846.
28. de Almeida-Pititto B, Dualib PM, Jordão MC *et al.* (2021) Branched-chain amino acids predict incident diabetes in the Brazilian longitudinal study of adult health-ELSA-Brasil. *Diabetes Res Clin Pract* **17**, 10874727.
29. Yu L, Song P, Zhu Q *et al.* (2022) The dietary branched-chain amino acids transition and risk of type 2 diabetes among Chinese adults from 1997 to 2015: based on seven cross-sectional studies and a prospective cohort study. *Front Nutr* **9**, 881847.
30. Ruiz-Canela M, Toledo E, Clish CB *et al.* (2016) Plasma branched-chain amino acids and incident cardiovascular disease in the PREDIMED trial. *Clin Chem* **62**, 582–592.
31. Tobias DK, Lawler PR, Harada PH *et al.* (2018) Circulating branched-chain amino acids and incident cardiovascular disease in a prospective cohort of US women. *Circ Genomic Precis Med* **11**, e002157.
32. Solon-Biet SM, Griffiths L, Fosh S *et al.* (2022) Meta-analysis links dietary branched-chain amino acids to metabolic health in rodents. *BMC Biol* **20**, 19.
33. Qin L-Q, Xun P, Bujnowski D *et al.* (2011) Higher branched-chain amino acid intake is associated with a lower prevalence of being overweight or obese in middle-aged East Asian and Western adults. *J Nutr* **141**, 249–54.
34. Elwood PC, Pickering JE, Givens DI *et al.* (2010) The consumption of milk and dairy foods and the incidence of vascular disease and diabetes: an overview of the evidence. *Lipids* **45**, 925–939.
35. Mente A, de Koning L, Shannon HS *et al.* (2009) A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Arch Intern Med* **169**, 659–669.
36. Soedamah-Muthu SS & Guo J (2020) Dairy consumption and cardiometabolic diseases: evidence from prospective studies. In *Milk and Dairy Foods: Their Functionality in Human Health and Disease*, pp. 1–28 [DI Givens, editor] Cambridge, MA: Academic Press/Elsevier.
37. Guo J, Astrup A, Lovegrove JA *et al.* (2017) Milk and dairy consumption and risk of cardiovascular diseases and all-cause mortality: dose–response meta-analysis of prospective cohort studies. *Eur J Epidemiol* **32**, 269–287.
38. Poppitt SD (2020) Cow's milk and dairy consumption: is there now consensus for cardiometabolic health? *Front Nutr* **7**, 574725.
39. Nestel PJ & Mori TA (2022) Dairy foods: is its cardiovascular risk profile changing? *Curr Atheroscler* **24**, 33–40.
40. Dehghan M, Mente A, Rangarajan S *et al.* (2018) Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. *Lancet* **392**, 2288–2297.
41. Givens DI (2021) Lipids and cardiovascular disease risks with a focus on dairy foods. In *Bioaccessibility and Digestibility of Lipids from Food*, pp. 101–110 [MM-L Grundy and PJ Wilde, editors] Cham, Switzerland: Springer Nature.
42. Sellem L, Flourakis M, Jackson KG *et al.* (2022) Impact of replacement of individual dietary SFAs on circulating lipids and other biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials in humans. *Adv Nutr* **13**, 1200–1225.
43. Olsson E, Larsson SC, Höjjer J *et al.* (2022) Milk and fermented milk consumption and risk of stroke: longitudinal study. *Nutrients* **14**, 1070.
44. Guo J, Givens DI & Heitmann BL (2022) Association between dairy consumption and cardiovascular disease events, bone fracture and all-cause mortality. *PLoS ONE* **17**, e0271168.
45. Guo N, Zhu Y, Tian D *et al.* (2022) Role of diet in stroke incidence: an umbrella review of meta-analyses of prospective observational studies. *BMC Med* **20**, 194.
46. Pimpin L, Wu JHY, Haskelberg H *et al.* (2016) Is butter back? A systematic review and meta-analysis of butter consumption and risk of cardiovascular disease, diabetes, and total mortality. *PLoS ONE* **11**, e0158118.
47. Brassard D, Tessier-Grenier M, Allaire J *et al.* (2017) Comparison of the impact of SFAs from cheese and butter on cardiometabolic risk factors: a randomized controlled trial. *Am J Clin Nutr* **105**, 800–809.
48. British Heart Foundation (2022) Heart and circulatory disease statistics 2022. [bhf-statistics-compendium-2022.pdf](https://www.bhf-statistics-compendium-2022.pdf) (accessed September 2022).
49. Public Health England (2017) Health matters: combatting high blood pressure. <https://www.gov.uk/government/publications/health-matters-combating-high-blood-pressure/health-matters-combating-high-blood-pressure> (accessed May 2022).
50. Engberink MF, Geleijnse JM, de Jong N *et al.* (2009) Dairy intake, blood pressure, and incident hypertension in a general Dutch population. *J Nutr* **139**, 582–587.
51. Ralston RA, Lee JH, Truby H *et al.* (2012) A systematic review and meta-analysis of elevated blood pressure and consumption of dairy foods. *J Hum Hypertens* **26**, 3–13.
52. Livingstone KM, Lovegrove JA, Cockcroft JR *et al.* (2013) Does dairy food intake predict arterial stiffness and blood pressure in men?: evidence from the Caerphilly prospective study. *Hypertension* **61**, 42–47.
53. Mansouri M, Pahlavani N, Sharifi F *et al.* (2020) Dairy consumption in relation to hypertension among a large population of university students: the MEPHASOUS study. *Diabetes Metab Syndr Obes Targets Ther* **13**, 1633–1642.



54. Schmidt KA, Cromer G, Burhans MS *et al.* (2021) Impact of low-fat and full-fat dairy foods on fasting lipid profile and blood pressure: exploratory endpoints of a randomized controlled trial. *Am J Clin Nutr* **114**, 882–892.
55. Kris-Etherton PM, Grieger JA, Hilpert KF *et al.* (2009) Milk products, dietary patterns and blood pressure management. *J Am Coll Nutr* **28**, 103S–119S.
56. Fekete AA, Giromini C, Chatzidiakou Y *et al.* (2016) Whey protein lowers blood pressure and improves endothelial function and lipid biomarkers in adults with prehypertension and mild hypertension: results from the chronic Whey2Go randomized controlled trial. *Am J Clin Nutr* **104**, 1534–1544.
57. Fekete AA, Giromini C, Chatzidiakou Y *et al.* (2018) Whey protein lowers systolic blood pressure and Ca-caseinate reduces serum TAG after a high-fat meal in mildly hypertensive adults. *Sci Rep* **8**, 5026.
58. Fekete AA, Givens DI & Lovegrove JA (2013) The impact of milk proteins and peptides on blood pressure and vascular function: a review of evidence from human intervention studies. *Nutr Res Rev* **26**, 177–190.
59. FitzGerald RJ & Meisel H (2000) Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. *Br J Nutr* **84**, S33–S37.
60. Maes W, Van Camp J, Vermeirssen V *et al.* (2004) Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by endothelial cells. *Regul Pept* **118**, 105–109.
61. Price D, Jackson KG, Lovegrove JA *et al.* (2022) The effects of whey proteins, their peptides, and amino acids on vascular function. *Nutr Bull* **47**, 9–26.
62. Oh YS (2018) Arterial stiffness and hypertension. *Clin Hypertens* **24**, 17.
63. Kesse-Guyot E, Vergnaud A-C, Fezeu L *et al.* (2010) Associations between dietary patterns and arterial stiffness, carotid artery intima-media thickness and atherosclerosis. *Eur J Cardiovasc Prev Rehabil* **17**, 718–724.
64. Vlachopoulos C, Aznaouridis K & Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol* **55**, 1318–1327.
65. Crichton GE, Elias MF, Dore GA *et al.* (2012) Relations between dairy food intake and arterial stiffness: pulse wave velocity and pulse pressure. *Hypertension* **59**, 1044–1051.
66. Ribeiro AG, Mill JG, Cade NV *et al.* (2018) Associations of dairy intake with arterial stiffness in Brazilian adults: the Brazilian longitudinal study of adult health (ELSA-Brasil). *Nutrients* **10**, 701.
67. Diez-Fernández A, Álvarez-Bueno C, Martínez-Vizcaíno V *et al.* (2019) Total dairy, cheese and milk intake and arterial stiffness: a systematic review and meta-analysis of cross-sectional studies. *Nutrients* **11**, 741.
68. Sanders TAB, Lewis FJ, Goff LM *et al.* (2013) SFAs do not impair endothelial function and arterial stiffness. *Am J Clin Nutr* **98**, 677–683.
69. Rose S *et al.* (1998) What is wrong with reductionist explanations of behaviour? In *Novartis Foundation Symposium 213, The Limits of Reductionism in Biology*, pp. 176–186 [GR Bock and JA Goode, editors]. Chichester: John Wiley and Sons Ltd.
70. Thorning TK, Bertram H, Bonjour J-P *et al.* (2017) Whole dairy matrix or single nutrients in assessment of health effects: current evidence and knowledge gaps. *Am J Clin Nutr* **105**, 1033–1045.
71. Feeney EL & McKinley MC (2020) The dairy food matrix: what it is and what it does. In *Milk and Dairy Foods: Their Functionality in Human Health and Disease*, pp. 205–225 [DI Givens, editor]. Cambridge, MA: Academic Press/Elsevier.
72. Mulet-Cabero A-I & Brodtkorb A (2021) Dairy products. In *Bioaccessibility and Digestibility of Lipids from Food*, pp. 133–149 [MM-L Grundy and PJ Wilde, editors]. Cham, Switzerland: Springer Nature.
73. Weaver CM (2021) Dairy matrix: is the whole greater than the sum of the parts? *Nutr Rev* **79**, (Suppl. 2) 4–15.
74. Feeney EL, Lamichhane P & Sheehan JJ (2021) The cheese matrix: understanding the impact of cheese structure on aspects of cardiovascular health – a food science and a human nutrition perspective. *Int J Dairy Technol* **74**, 656–670.
75. Hjerpsted J, Leedo E & Tholstrup T (2011) Cheese intake in large amounts lowers LDL-cholesterol concentrations compared with butter intake of equal fat content. *Am J Clin Nutr* **94**, 1479–1484.
76. Vissers LET, Rijkse J, Boer JMA *et al.* (2019) Fatty acids from dairy and meat and their association with risk of coronary heart disease. *Eur J Nutr* **58**, 2639–2647.
77. Feeney EL, Barron R, Dible V *et al.* (2018) Dairy matrix effects: response to consumption of dairy fat differs when eaten within the cheese matrix—a randomized controlled trial. *Am J Clin Nutr* **108**, 667–674.
78. Lorenzen JK & Astrup A (2011) Dairy calcium intake modifies responsiveness of fat metabolism and blood lipids to a high-fat diet. *Br J Nutr* **105**, 1823–1831.
79. Bosworth AW, Bowditch HI & Giblin LA (1918) Studies of infant feeding. X: the digestion and absorption of fats. I. Calcium in its relation to the absorption of fatty acids. *Am J Dis Child* **XV**, 397–407.
80. Lamothe S, Rémillard N, Tremblay J *et al.* (2017) Influence of dairy matrices on nutrient release in a simulated gastrointestinal environment. *Food Res Int* **92**, 138–146.
81. Astrup A, Bertram HCS, Bonjour J-P *et al.* (2019) WHO draft guidelines on dietary saturated and trans fatty acids: time for a new approach? *BMJ* **365**, 14137.
82. Astrup A, Magkos F, Bier DM *et al.* (2020) Saturated fats and health: a reassessment and proposal for food-based recommendations, *JACC* state-of-the-art review. *J Am Coll Cardiol* **76**, 844–857.
83. Astrup A, Teicholz N, Magkos F *et al.* (2021) Dietary saturated fats and health: are the US guidelines evidence-based? *Nutrients* **13**, 3305.
84. SACN (Scientific Advisory Committee on Nutrition) (2019) Saturated fats and health. <https://www.gov.uk/government/publications/saturated-fats-and-health-sacn-report> (accessed May 2022).
85. Public Health England (2020) National Diet and Nutrition Survey, Results from years 9–11 of the Rolling Programme 2016/17–2018/19. <https://www.gov.uk/government/statistics/ndns-results-from-years-9-to-11-2016-to-2017-and-2018-to-2019> (accessed May 2022).
86. US DHHS (U.S. Department of Health and Human Services and U.S. Department of Agriculture) (2015) 2015–2020 Dietary guidelines for Americans. Eighth edition. <http://health.gov/dietaryguidelines/2015/guidelines/> (accessed May 2022).
87. Eckel RH, Jakicic JM, Ard JD *et al.* (2014) 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* **129**, S76–S99.
88. Vessby B (2003) Dietary fat, fatty acid composition in plasma and the metabolic syndrome. *Curr Opin Lipidol* **14**, 15–19.

89. Riccardi G, Giacco R & Rivellese AA (2004) Dietary fat, insulin sensitivity and the metabolic syndrome. *Clin Nutr* **23**, 447–456.
90. Risérus U, Willett WC & Hu FB (2009) Dietary fats and prevention of type 2 diabetes. *Prog Lipid Res* **48**, 44–51.
91. de Souza RJ, Mente A, Maroleanu A *et al.* (2015) Intake of saturated and trans unsaturated fatty acids and risk of all-cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. *BMJ* **351**, h3978.
92. Imamura F, Micha R, Wu JHY *et al.* (2016) Effects of saturated fat, polyunsaturated fat, monounsaturated fat, and carbohydrate on glucose-insulin homeostasis: a systematic review and meta-analysis of randomised controlled feeding trials. *PLoS Med* **13**, e1002087.
93. Jovanovski E, Li D, Thanh H *et al.* (2017) The effect of alpha-linolenic acid on glycemic control in individuals with type 2 diabetes. A systematic review and meta-analysis of randomized controlled clinical trials. *Medicine* **96**, e6531.
94. Gao H, Geng T, Huang T *et al.* (2017) Fish oil supplementation and insulin sensitivity: a systematic review and meta-analysis. *Lipids Health Dis* **16**, 131.
95. Rice Bradley BH (2018) Dietary fat and risk for type 2 diabetes: a review of recent research. *Cur Nutr Rep* **7**, 214–226.
96. Liu S, van der Schouw YT, Soedamah-Muthu SS *et al.* (2019) Intake of dietary saturated fatty acids and risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition Netherlands cohort: associations by types, sources of fatty acids and substitution by macronutrients. *Eur J Nutr* **58**, 1125–1136.
97. Neuenschwander M, Barbaresko J, Pischke CR *et al.* (2020) Intake of dietary fats and fatty acids and the incidence of type 2 diabetes: a systematic review and dose-response meta-analysis of prospective observational studies. *PLoS Med* **17**, e1003347.
98. Sobczak AIS, Blindauer CA & Stewart AJ (2019) Changes in plasma free fatty acids associated with type 2 diabetes. *Nutrients* **11**, 2022.
99. Livingstone KM, Brayner B, Celis-Morales C *et al.* (2022) Associations between dietary patterns, FTO genotype and obesity in adults from seven European countries. *Eur J Nutr* **61**, 2953–2965.
100. Siri-Tarino PW, Sun Q, Hu FB *et al.* (2010) Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. *Am J Clin Nutr* **91**, 535–546.
101. Chowdhury R, Warnakula S, Kunutsor S *et al.* (2014) Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. *Ann Intern Med* **160**, 398–406.
102. Mente A, Dehghan M, Rangarajan S *et al.* (2017) Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. *Lancet Diabetes Endocrinol* **5**, 774–787.
103. Heileson JL (2019) Dietary saturated fat and heart disease: a narrative review. *Nutr Rev* **78**, 474–485.
104. Mazidi M, Mikhailidis DP, Sattar N *et al.* (2020) Association of types of dietary fats and all-cause and cause-specific mortality: a prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. *Clin Nutr* **39**, 3677–3686.
105. Kim Y, Je Y & Giovannucci EL (2021) Association between dietary fat intake and mortality from all-causes, cardiovascular disease, and cancer: a systematic review and meta-analysis of prospective cohort studies. *Clin Nutr* **40**, 1060–1070.
106. Schwingshackl L, Zähringer J, Beyerbach J *et al.* (2021) Total dietary fat intake, fat quality, and health outcomes: a scoping review of systematic reviews of prospective studies. *Ann Nutr Metab* **77**, 4–15.
107. DuBroff R & de Lorgeril M (2021) Fat or fiction: the diet-heart hypothesis. *BMJ Evidence-based Medicine* **26**, 3–7.
108. Ramsden CE, Zamora D, Leelarthaepin B *et al.* (2013) Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. *BMJ* **346**, e8707.
109. Ramsden CE, Zamora D, Majchrzak-Hong SF *et al.* (2016) Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968–73). *BMJ* **353**, i1246.
110. Sacks FM, Lichtenstein AH, Wu JHY, Appel LJ, Creager MA, Kris-Etherton PM *et al.* (2017) Dietary fats and cardiovascular disease: a Presidential Advisory from the American Heart Association. *Circulation* **136**, e1–e3.
111. Hooper L, Martin N, Jimoh OF *et al.* (2020) Reduction in saturated fat intake for cardiovascular disease. *Cochrane Database Syst Rev Issue* **5**, CD011737.
112. Forouhi NG, Koulman A, Sharp SJ *et al.* (2014) Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. *Lancet Diabetes Endocrinol* **2**, 810–818.
113. Prada M, Wittenbecher C, Eichelmann F *et al.* (2021) Association of the odd-chain fatty acid content in lipid groups with type 2 diabetes risk: a targeted analysis of lipidomics data in the EPIC-Potsdam cohort. *Clin Nutr* **40**, 4988–4999.
114. Imamura F, Fretts AM, Marklund *et al.* (2020) Fatty acids in the *de novo* lipogenesis pathway and incidence of type 2 diabetes: a pooled analysis of prospective cohort studies. *PLoS Med* **16**, e1003102.
115. Murru E, Manca C, Carta G *et al.* (2022) Impact of palmitic acid on lipid metabolism. *Front Nutr* **9**, 861664.
116. Schwarz J-M, Linfoot P, Dare D *et al.* (2003) Hepatic *de novo* lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. *Am J Clin Nutr* **77**, 43–50.
117. Siri-Tarino PW, Chiu S, Bergeron N *et al.* (2015) Saturated fats versus polyunsaturated fats versus carbohydrates for cardiovascular disease prevention and treatment. *Annu Rev Nutr* **35**, 517–543.
118. Dawczynski C, Kleber ME, März W *et al.* (2015) Saturated fatty acids are not off the hook. *Nutr Metab Cardiovasc Dis* **25**, 1071–1078.
119. Mensink RP, Zock PL, Kester AD *et al.* (2003) Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr* **77**, 1146–1155.
120. Borén JM, Chapman J, Krauss RM *et al.* (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J* **41**, 2313–2330.
121. Quispe R, Elshazly MB, Zhao D *et al.* (2020) Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence



- of atherosclerotic cardiovascular disease in primary prevention: the ARIC study. *Eur J Prev Cardiol* **27**, 1597–1605.
122. Mathews SC, Mallidi J, Kulkarni K *et al.* (2012) Achieving secondary prevention low-density lipoprotein particle concentration goals using lipoprotein cholesterol-based data. *PLoS ONE* **7**, e33692.
123. Griffin BA, Mensink RP & Lovegrove JA (2021) Does variation in serum LDL-cholesterol response to dietary fatty acids help explain the controversy over fat quality and cardiovascular disease risk? *Atherosclerosis* **328**, 108–113.
124. O'Connor A, Feeney EL, Bhargava N *et al.* (2022) Determination of factors associated with serum cholesterol response to dairy fat consumption in overweight adults: secondary analysis from an RCT. *Front Nutr* **9**, 945723.
125. Arsenault BJ, Lemieux I, Despres JP *et al.* (2007) Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk Prospective Population Study. *Eur Heart J* **28**, 2770–2777.
126. Hoogeveen RC, Gaubatz JW, Sun W *et al.* (2014) Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the atherosclerosis risk in communities (ARIC) study. *Arterioscler Thromb Vasc Biol* **34**, 1069–1077.
127. Grammer TB, Kleber ME, Marz W *et al.* (2015) Low-density lipoprotein particle diameter and mortality: the Ludwigshafen risk and cardiovascular health study. *Eur Heart J* **36**, 31–38.
128. Froyen E (2021) The effects of fat consumption on low density lipoprotein particle size in healthy individuals: a narrative review. *Lipids Health Dis* **20**, 86.
129. Bergeron N, Chiu S, Williams PT *et al.* (2019) Effects of red meat, white meat, and nonmeat protein sources on atherogenic lipoprotein measures in the context of low compared with high saturated fat intake: a randomized controlled trial. *Am J Clin Nutr* **110**, 24–33.
130. Vasilopoulou D, Markey O, Kliem KE *et al.* (2020) Reformulation initiative for partial replacement of saturated with unsaturated fats in dairy foods attenuates the increase in low-density lipoprotein cholesterol and improves flow-mediated dilatation compared with conventional dairy: the randomized, controlled RESET study. *Am J Clin Nutr* **111**, 739–748.
131. Sjogren P, Rosell M, Skoglund-Andersson C *et al.* (2004) Milk-derived fatty acids are associated with a more favorable LDL particle size distribution in healthy men. *J Nutr* **134**, 1729–1735.
132. de Oliveira Otto MC, Mozaffarian D, Kromhout D *et al.* (2012) Dietary intake of saturated fat by food source and incident cardiovascular disease: the multi-ethnic study of atherosclerosis. *Am J Clin Nutr* **96**, 397–404.
133. Praagman J, Beulens JWJ, Alsema M *et al.* (2016) The association between dietary saturated fatty acids and ischemic heart disease depends on the type and source of fatty acid in the European Prospective Investigation into Cancer and Nutrition–Netherlands cohort. *Am J Clin Nutr* **103**, 356–365.
134. Bechthold A, Boeing H, Schwedhelm C *et al.* (2019) Food groups and risk of coronary heart disease, stroke and heart failure: a systematic review and dose–response meta-analysis of prospective studies. *Crit Rev Food Sci Nutr* **59**, 1071–1090.
135. Di Angelantonio E, Sarwar N, Perry P *et al.* (2009) Major lipids, apolipoproteins, and risk of vascular disease. *JAMA* **302**, 1993–2000.
136. Sharrett AR, Ballantyne CM, Coady SA *et al.* (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A–I and B, and HDL density subfractions the atherosclerosis risk in communities (ARIC) study. *Circulation* **104**, 1108–1113.
137. Madsen CM, Varbo A & Nordestgaard BG (2017) Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. *Eur Heart J* **38**, 2478–2486.
138. Keene D, Price C, Shun-Shin MJ *et al.* (2014) Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients. *BMJ* **349**, g4379.
139. Griffin BA & Lovegrove JA (2018) Butter increases HDL functional capacity: is this compensation for its adverse effect on serum LDL cholesterol? *J Nutr* **148**, 1069–1070.
140. Krauss RM & Kris-Etherton PM (2020) Public health guidelines should recommend reducing saturated fat consumption as much as possible: NO. *Am J Clin Nutr* **112**, 19–24.
141. de Goede J, Soedamah-Muthu SS, Pan A *et al.* (2016) Dairy consumption and risk of stroke: a systematic review and updated dose–response meta-analysis of prospective cohort studies. *J Am Heart Assoc* **5**, e002787.
142. Gijsbers L, Ding EL, Malik VS *et al.* (2016) Consumption of dairy foods and diabetes incidence: a dose–response meta-analysis of observational studies. *Am J Clin Nutr* **103**, 1111–1124.